BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CMSA - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://cmsa.fas.harvard.edu
X-WR-CALDESC:Events for CMSA
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211007T184100
DTEND;TZID=America/New_York:20211007T184100
DTSTAMP:20240214T083403Z
CREATED:20240214T083403Z
LAST-MODIFIED:20240214T083403Z
UID:10002590-1633632060-1633632060@cmsa.fas.harvard.edu
SUMMARY:10/7/2021 Interdisciplinary Science Seminar
DESCRIPTION:Title: SiRNA Targeting TCRb: A Proposed Therapy for the Treatment of Autoimmunity \nAbstract: As of 2018\, the United States National Institutes of Health estimate that over half a billion people worldwide are affected by autoimmune disorders. Though these conditions are prevalent\, treatment options remain relatively poor\, relying primarily on various forms of immunosuppression which carry potentially severe side effects and often lose effectiveness over time. Given this\, new forms of therapy are needed. To this end\, we have developed methods for the creation of small-interfering RNA (siRNA) for hypervariable regions of the T-cell receptor β-chain gene (TCRb) as a highly targeted\, novel means of therapy for the treatment of autoimmune disorders. \nThis talk will review the general mechanism by which autoimmune diseases occur and discuss the pros and cons of conventional pharmaceutical therapies as they pertain to autoimmune disease treatment. I will then examine the rational and design methodology for the proposed siRNA therapy and how it contrasts with contemporary methods for the treatment of these conditions. Additionally\, the talk will compare the efficacy of multiple design strategies for such molecules by comparison over several metrics and discuss how this will be guiding future research.
URL:https://cmsa.fas.harvard.edu/event/10-7-2021-interdisciplinary-science-seminar/
CATEGORIES:Interdisciplinary Science Seminar
END:VEVENT
END:VCALENDAR